Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee
NCT04119687Phase 1Active, not recruiting
- Sponsor
- Pacira BioSciences
- Start
- Mar 2020
- Primary completion
- Nov 2023
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of enekinragene inzadenovec in osteoarthritis (OA) (3 arms), sponsored by Pacira BioSciences. Primary endpoint: Incidence of treatment emergent adverse events. Started Mar 2020; status: active, not recruiting.
02
Drugs
enekinragene inzadenovec
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04119687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04119687.